Table 1.
Baseline characteristics
| Overall population (n = 24658) |
AF (n = 740) | No AF (n = 23918) | P value | |
|---|---|---|---|---|
| Demographics | ||||
| Age(years) | 63 (53–72) | 73 (65–79) | 63 (53–72) | <0.01 |
| Men | 74.2 | 64.9 | 74.5 | <0.01 |
| Medical history | ||||
| Previous angina pectoris | 28.2 | 32.0 | 28.0 | 0.02 |
| PreviousMI | 7.7 | 7.9 | 7.6 | 0.81 |
| PreviousPCI/CABG | 5.2 | 4.5 | 5.2 | 0.37 |
| Previous heart failure | 2.6 | 7.7 | 2.4 | <0.01 |
| Previous stroke | 9.5 | 17.8 | 9.2 | <0.01 |
| Previous peripheral arterial disease | 0.6 | 1.1 | 0.6 | 0.15 |
| Chronic renal failure | 1.4 | 1.7 | 1.4 | 0.60 |
| Cardiovascular risk factors | ||||
| Hypertension | 51.5 | 59.3 | 51.2 | <0.01 |
| Hyperlipidemia | 8.0 | 6.3 | 8.1 | 0.10 |
| Diabetes mellitus | 20.0 | 18.8 | 20.0 | 0.44 |
| Family history of premature CAD | 4.0 | 3.0 | 4.0 | 0.12 |
| Current smoker | 54.7 | 44.7 | 55.0 | <0.01 |
| Clinical characteristics | ||||
| STEMI | 75.7 | 65.7 | 76.0 | <0.01 |
| LVEF(%) | 55(47–60) | 50(41–59) | 55(47–60) | <0.01 |
| Killip classification III-IV | 9.2 | 24.2 | 8.7 | <0.01 |
| CHA2DS2-VASc ≥ 2 | 46.1 | 66.1 | 45.5 | <0.01 |
| HAS-BLED ≥ 3 | 11.1 | 21.4 | 10.8 | <0.01 |
| GRACE Score | 129 (112–149) | 161 (133–182) | 129 (112–146) | <0.01 |
| TIMI Score | ||||
| STEMI | 4 (2–6) | 6 (4–8.5) | 4 (2–6) | <0.01 |
| NSTEMI | 2(2–3) | 2(2–3) | 2(1–3) | <0.01 |
| Treatments | ||||
| Reperfusion Therapy | 48.0 | 35.9 | 48.3 | <0.01 |
| PCI | 40.2 | 29.7 | 40.5 | <0.01 |
| Fibrinolysis | 7.8 | 6.2 | 7.8 | <0.01 |
| ACE/ARB | 59.7 | 54.8 | 59.9 | 0.02 |
| β-blockers | 69.9 | 59.9 | 70.2 | <0.01 |
| Anti-arrhythmia drugs | 9.8 | 45.4 | 8,7 | <0.001 |
Data are presented as median (IQR) or %
AF atrial fibrillation, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CAD coronary artery disease, LVEF left ventricular ejection fraction, GRACE global registry of acute coronary events, TIMI thrombolysis in myocardial infarction, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, ACEI angiotensin-converting enzyme, ARB angiotensin receptor blocker